non-communicable disease
progression of motor handicap
conservative iron chelation therapy
randomized clinical trial of deferiprone Parkinson’s disease
novel iron chelation therapy
progression of handicap
Excess iron
non-motor handicap scores
early PD patients
novo PD patients
Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale
change
cell models of PD
placebo
parallel-group
project
primary efficacy criterion
secondary efficacy criterion
mitochondrial disorders
industrial research
international research
multicentre trial
neurodegenerative diseases
month wash
pilot clinical studies
prototypic drug deferiprone
moderate-dose DFP
o-methyl transferase
powerful antioxidant effect
frequent neurodegenerative disorder
biological biomarkers
dopaminergic neurons
health economics
multicentric
tetrahydropyridine mouse model
high levels of oxidative stress
inhibition of catechol
substantia nigra pars compacta
strategy
societal impacts
innovation activities
phenyl
neuroprotection
treatment
study results
dopamine metabolism
systemic parameters
baseline
brain
weeks
regional siderosis
period
symptomatic effects
day